Atazanavir ritonavir — Competitive Intelligence Brief

Atazanavir ritonavir (Atazanavir ritonavir) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: HIV protease inhibitor. Area: Infectious Disease.

marketed HIV protease inhibitor HIV protease Infectious Disease Small molecule

Target snapshot

Atazanavir ritonavir (Atazanavir ritonavir) — Göteborg University. Atazanavir is a protease inhibitor that blocks HIV protease, preventing viral polyprotein cleavage and maturation; ritonavir is a booster that inhibits cytochrome P450 metabolism to increase atazanavir levels.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Atazanavir ritonavir TARGET	Atazanavir ritonavir	Göteborg University	marketed	HIV protease inhibitor	HIV protease
Darunavir ritonavir	Darunavir ritonavir	St Stephens Aids Trust	marketed	HIV protease inhibitor (boosted)	HIV protease
lopinavir/ritonavir and raltegravir	lopinavir/ritonavir and raltegravir	Saint Michael's Medical Center	marketed	Protease inhibitor (lopinavir/ritonavir) and integrase strand transfer inhibitor (raltegravir)	HIV protease (lopinavir/ritonavir) and HIV integrase (raltegravir)
Lopinavir/ritonavir simplification strategy	Lopinavir/ritonavir simplification strategy	Fundación Huésped	marketed	Protease inhibitor combination	HIV protease
First-line Antiretroviral Therapy	First-line Antiretroviral Therapy	UPECLIN HC FM Botucatu Unesp	marketed	Antiretroviral combination therapy (NRTI/NNRTI/PI/INSTI)	HIV reverse transcriptase, HIV protease, HIV integrase (depending on regimen components)
protease inhibitors	protease inhibitors	French National Agency for Research on AIDS and Viral Hepatitis	marketed	Protease inhibitor	HIV protease
Standard Triple	Standard Triple	University of Alberta	marketed	Antiretroviral combination therapy	HIV reverse transcriptase, HIV protease (depending on formulation)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (HIV protease inhibitor class)

1. Bristol-Myers Squibb · 5 drugs in this class
2. ViiV Healthcare · 3 drugs in this class
3. GlaxoSmithKline · 2 drugs in this class
4. Drugs for Neglected Diseases · 2 drugs in this class
5. Germans Trias i Pujol Hospital · 2 drugs in this class
6. Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) · 1 drug in this class
7. DualityBio Inc. · 1 drug in this class
8. French National Agency for Research on AIDS and Viral Hepatitis · 1 drug in this class
9. Far East Bio-Tec Co., Ltd · 1 drug in this class
10. Community Research Initiative of New England · 1 drug in this class